EZH2 inhibitors show promise in regenerating insulin-producing cells for type 1 diabetes treatment

  • Post author:
  • Post category:uncategorized

Study explores the potential of EZH2 inhibitors GSK126 and Tazemetostat in stimulating β-cell regeneration from pancreatic ductal progenitor cells, offering a novel therapeutic approach for Type 1 Diabetes.